Drug Interaction Report

Ventricular pauses and bradycardia, mostly asymptomatic, have been observed in clinical studies with ticagrelor. Theoretically, the risk of symptomatic bradycardia may be increased during concomitant use of other agents known to induce bradycardia. However, in PLATO, a large, randomized, double-blind efficacy and safety comparison study with clopidogrel in patients with acute coronary syndromes, no evidence of clinically significant adverse interactions was observed during concomitant administration with one or more drugs known to induce bradycardia including beta-blockers (96%), the calcium channel blockers diltiazem and verapamil (33%), and digoxin (4%).